Conclusion and Results
In 2023, one and a half weeks after her final dose of intravenous ketamine 1200 milligrams, her pain remained 4 out of 10. The patient consumed 2 grams, 5.5 grams, and then 3.5 grams of psilocybe cubensis mushrooms. The second dose was three days after the first, and the third was two days later. Alongside dosing sessions, the patient partook in adjunctive neuromechanics, neurovisual modulation, and tactile reprocessing programming. Leading up to the psilocybin dosing, she had tried these adjunctive techniques alone without concurrent psilocybin use, but did not achieve significant relief.
At one month follow-up, the pain decreased to 0 to 1 out of 10 as recorded by the Brief Pain Inventory (BPI). She also endorsed a decrease in mood symptoms at follow-up, supported by Montgomery-Asberg Depression Rating Scale (MADRS), Hamilton Depression Rating Scale (HAM-D), and Clinician-Administered PTSD Scale (CAPS) scores, as reflected in Table 1.
Her CRPS pain remained at 0 to 1 out of 10 without ketamine for 9 months. The frequency of her falls decreased by 75%, with only two falls in the 9-month period since starting psilocybin, a significant improvement from before. Additionally, the frequency, intensity, and duration of glossodynia attacks have reduced by 75% each. She reports that the attack intensity no longer rises above 2 out of 10. No long-term adverse events after psilocybin were noted.